Evidence map›Paper›PMID 35199329›Full record

ReviewHistology and histopathology2022

Mdivi-1: a promising drug and its underlying mechanisms in the treatment of neurodegenerative diseases.

Xiaoqin Liu, Lijuan Song, Jiezhong Yu, Fang Huang, Yanhua Li, Cungen Ma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Histology and histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Mitochondria in Alzheimer's Disease Pathogenesis.Life (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiaoqin LiuInstitute of Brain Science, Shanxi Datong University, Datong, China.
Lijuan SongThe Key Research Laboratory of Benefiting Qi for Acting Blood Circulation Method to Treat Multiple Sclerosis of State Administration of Traditional Chinese Medicine/Research Center of Neurobiology, Shanxi University of Chinese Medicine, Jinzhong, China.
Jiezhong YuInstitute of Brain Science, Shanxi Datong University, Datong, China.
Fang HuangInstitute of Brain Science, Shanxi Datong University, Datong, China.
Yanhua LiInstitute of Brain Science, Shanxi Datong University, Datong, China.
Cungen MaInstitute of Brain Science, Shanxi Datong University, Datong, China.
Shanxi Datong University · CNShanxi Medical University · CN

Funding

China Postdoctoral Science Foundation 2020M680912Fundamental Research Project for Application of Datong 2021174National Natural Science Foundation of China 82004028Scientific and Technological Innovation Program of Higher Education Institutions in Shanxi 2020L0497Shanxi Scholarship Council of China HGKY2019089Youth Project of Basic Research Program of Shanxi Province 20210302123475Youth Project of Basic Research Program of Shanxi Province 20210302124276
6 · The paper itself

Abstract

Mitochondria are energy-producing organelles, and neurons are high energy consumption cells. Therefore, mitochondrial dysfunction is a critical factor in neurodegenerative processes. Mitochondrial division inhibitor-1 (Mdivi-1) is a small chemical inhibitor of mitochondrial division dynamin, which plays multiple roles in mitochondrial dynamics, mitochondrial autophagy, ATP production, the immune response, and Ca²⁺ homeostasis. Mdivi-1 inhibition of excessive mitochondrial fission exerted cytoprotective effects in neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). Mdivi-1 changed the mRNA expression of the electron transport chain (ETC) and reduced Ca²⁺ overload against neuronal injury. Elucidation of the molecular mechanism of Mdivi-1 in neurodegenerative diseases will help evaluate its therapeutic potential and promote its application in clinical studies. The present article focused on the multiple effects of Mdivi-1 on mitochondrial function and its potential therapeutic effects in neurodegenerative diseases.

Indexed as

Mitochondrial DynamicsNeurodegenerative DiseasesCalciumDynaminsHumansQuinazolinones3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinoneCalciumDynaminsQuinazolinones

Identifiers

PMID35199329
OpenAlexW4214736639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.